Xencor stock hits 52-week high at 21.34 USD By Investing.com

Xencor Inc.'s stock has reached a new 52-week high of $21.34, trading at $21.40, marking a significant recovery and a 154.93% surge over the past year. This growth is attributed to the biotechnology company's focus on developing engineered monoclonal antibodies for cancer and autoimmune diseases, though InvestingPro suggests the stock may be overvalued. The company is set to report earnings soon and will present Phase 1 study results for its XmAb819 antibody at the ESMO Congress 2026.